Martin Peter Carroll

Martin Peter Carroll, MD is an Associate Professor of Medicine specializing in Hematology-Oncology at the University of Pennsylvania's Perelman School of Medicine. He is a Penn Medicine physician whose clinical practice focuses exclusively on inpatient services. While affiliated with the Hospital of the University of Pennsylvania, he does not have privileges to treat patients in the hospital.

Dr. Carroll's research centers on acute myeloid leukemia (AML), with particular expertise in TP53 mutations, targeted therapies, drug resistance mechanisms, and the bone marrow microenvironment. His work spans both basic science investigations and clinical studies, with recent publications in high-impact journals including Cell, Cancer Cell, and Journal of Clinical Investigation. His research has explored menin inhibitors, metabolic pathways in leukemia cells, splicing factor mutations, and novel combination therapies for AML.

Analysis of Dr. Carroll's recent publications (2022-2025) reveals a strong focus on understanding treatment resistance mechanisms in AML, particularly related to TP53 mutations. His work demonstrates expertise in both laboratory-based research on leukemia biology and clinical studies evaluating treatment effectiveness. The publications span multiple subfields including molecular biology, cancer metabolism, epigenetics, and clinical oncology, reflecting a comprehensive approach to understanding and treating AML.

• Multiple publications on TP53 mutant AML and resistance mechanisms
• Research on metabolic pathways in leukemia cells
• Studies of targeted therapies including menin inhibitors and combination approaches
• Clinical research evaluating real-world treatment effectiveness

Dr. Carroll maintains active collaborations with researchers both within the University of Pennsylvania and internationally. His publication record demonstrates consistent productivity and engagement with cutting-edge research questions in hematology-oncology, particularly in the challenging area of treatment-resistant acute myeloid leukemia.